国产成人久久精品二区三区,无码少妇丰满熟妇一区二区

萊克多巴胺
NMR and HPLC COA下載 MSDS下載
Names：
Ractopaminehydrochloride
CAS號：
97825-25-7
MDL Number： MFCD00870322
MF(分子式)： C14H17N MW(分子量)： 301.38
EINECS:NA Reaxys Number:
Pubchem ID:56052 Brand:BIOFOUNT

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)是腎上腺素β激動劑，萊克多巴胺是選擇性結合并激活β-腎上腺素受體的藥物。萊克多巴胺又稱為4-（1-羥基-2-{[[4-（4-羥基苯基）丁-2-基]氨基}乙基）苯酚，萊克多巴胺是仲氨基化合物，萊克多巴胺是4-（2-氨基-1-羥基乙基）苯酚，其中與氮相連的氫之一被4-（對羥基苯基）丁-2-基取代。萊克多巴胺是一種多酚，一種仲氨基化合物，萊克多巴胺一種芐醇和一種仲醇。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
JSH60818-100mg	100mg	＞95%	￥ 1512.00	￥ 1512.00		Backorder	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	萊克多巴胺(97825-25-7);萊克多巴胺鹽酸鹽;丁胺;雷帕明; 雷帕明99％; 4-羥基-α-[[[[3-（4-羥基苯基）-1-甲基丙基]氨基]甲基]苯甲醇; el737; 4- [3- [2-羥基-2-（4-羥苯基）-乙基]氨基丁基]苯酚；4-羥基-α-[[[[[3-（4-羥基苯基）-1-甲基丙基]氨基]甲基]苯甲醇;
英文別名	Ractopaminehydrochloride(97825-25-7);4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)benzenemethanol;El 737;EL-737;LY 031537;LY-031537;ractopamine;ractopamine;hydrochloride;4-(1-Hydroxy-2-{[4-(4-hydroxyphenyl)-2-butanyl]amino}ethyl)phenol;RACTOPAMINE; RACTOPAMINE 99%; 4-Hydroxy-a-[[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]methyl]benzenemethanol; el737; 4-[3-[2-Hydroxy-2-(4-hydroxyphenyl)-ethyl]aminobutyl]phenol; 4-Hydroxy-α-[[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]methyl]benzenemethanol;
CAS號	97825-25-7
Inchi	InChI=1S/C18H23NO3/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15/h4-11,13,18-22H,2-3,12H2,1H3CopyCopied
InchiKey	XFZJEEAOWLFHDH-UKWJTHFESA-NCopyCopied
分子式 Formula	C14H17N
分子量 Molecular Weight	301.38
溶解度Solubility	在水中，在25°C（est）下為4.1X10 + 3 mg / L
性狀	off-white or light-yellow powder
儲藏條件 Storage conditions	storage at -4℃ (6-12weeks), longer storage period at -20℃ (1-2years)，0℃條件下運輸

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)毒理性質：

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. An 8-wk study of the effects of CLA, rendered animal fats, and ractopamine, and their interactive effects on growth, fatty acid composition, and carcass quality of genetically lean pigs was conducted. Gilts (n = 228; initial BW of 59.1 kg) were assigned to a 2 x 2 x 3 factorial arrangement consisting of CLA, ractopamine, and fat treatments. The CLA treatment consisted of 1% CLA oil (CLA-60) or 1% soybean oil. Ractopamine levels were either 0 or 10 ppm. Fat treatments consisted of 0% added fat, 5% choice white grease (CWG), or 5% beef tallow (BT). The CLA and fat treatments were initiated at 59.1 kg of BW, 4 wk before the ractopamine treatments. The ractopamine treatments were imposed when the gilts reached a BW of 85.7 kg and lasted for the duration of the final 4 wk until carcass data were collected. Lipids from the belly, outer and inner layers of backfat, and LM were extracted and analyzed for fatty acid composition from 6 pigs per treatment at wk 4 and 8. Feeding CLA increased (P < 0.02) G:F during the final 4 wk. Pigs fed added fat as either CWG or BT exhibited decreased (P < 0.05) ADFI and increased (P < 0.01) G:F. Adding ractopamine to the diet increased (P < 0.01) ADG, G:F, and final BW. The predicted carcass lean percentage was increased (P < 0.05) in pigs fed CLA or ractopamine. Feeding either 5% fat or ractopamine increased (P < 0.05) carcass weight. Adding fat to the diets increased (P < 0.05) the 10th rib backfat depth but did not affect predicted percent lean. Bellies of gilts fed CLA were subjectively and objectively firmer (P < 0.01). Dietary CLA increased (P < 0.01) the concentration of saturated fatty acids and decreased (P < 0.01) the concentration of unsaturated fatty acids of the belly fat, both layers of backfat, and LM. Ractopamine decreased (P < 0.01) the i.m. fat content of the LM but had relatively little effect on the fatty acid profiles of the tissues compared with CLA. These results indicate that CLA, added fat, and ractopamine work mainly in an additive fashion to enhance pig growth and carcass quality. Furthermore, these results indicate that CLA results in more saturated fat throughout the carcass.

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產(chǎn)生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：萊克多巴胺試劑,萊克多巴胺雜質,萊克多巴胺中間體,萊克多巴胺合成,萊克多巴胺密度,萊克多巴胺溶解度,萊克多巴胺旋光度,萊克多巴胺閃點,萊克多巴胺熔點,萊克多巴胺購買,

產(chǎn)品說明	萊克多巴胺(97825-25-7)僅用于科學研究實驗使用,不得用于其他用途,萊克多巴胺溶解度,萊克多巴胺MSDS,萊克多巴胺結構式詳見主頁.
Introduction	萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)is an adrenergic beta agonist, and ractopamine is a drug that selectively binds to and activates beta-adrenergic receptors.
Application1	萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)是腎上腺素β激動劑，萊克多巴胺是選擇性結合并激活β-腎上腺素受體的藥物。
Application2
Application3

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)藥理學：

1、萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)是腎上腺素β激動劑，萊克多巴胺是選擇性結合并激活β-腎上腺素受體的藥物。

2、克多巴胺又稱為4-（1-羥基-2-{[[4-（4-羥基苯基）丁-2-基]氨基}乙基）苯酚，萊克多巴胺是仲氨基化合物，萊克多巴胺是4-（2-氨基-1-羥基乙基）苯酚，其中與氮相連的氫之一被4-（對羥基苯基）丁-2-基取代。萊克多巴胺是一種多酚，一種仲氨基化合物，萊克多巴胺一種芐醇和一種仲醇。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H333吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P313獲得醫(yī)療建議/護理
備注	萊克多巴胺鹽酸鹽實驗過程中防止吸入、食入，做好安全防護

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)意外泄漏措施：

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Smith DJ, Shelver WL: Tissue residues of ractopamine and urinary excretion of ractopamine and metabolites in animals treated for 7 days with dietary ractopamine. J Anim Sci. 2002 May;80(5):1240-9. [PM

Chen XA, Huang PJ, Hou DB, Kang XS, Zhang GX, Zhou ZK: [Terahertz time-domain spectroscopy of ractopamine hydrochloride]. Guang Pu Xue Yu Guang Pu Fen Xi. 2011 Mar;31(3):600-3. [PMID:21595199]

Adeola O, Darko EA, He P, Young LG: Manipulation of porcine carcass composition by ractopamine. J Anim Sci. 1990 Nov;68(11):3633-41. [PMID:1979784]

Athayde NB, Dalla Costa OA, Roca RO, Guidoni AL, Ludtke CB, Oba E, Takahira RK, Lima GJ: Stress susceptibility in pigs supplemented with ractopamine. J Anim Sci. 2013 Sep;91(9):4180-7. doi: 10.2527/ja

Scramlin SM, Carr SN, Parks CW, Fernandez-Duenas DM, Leick CM, McKeith FK, Killefer J: Effect of ractopamine level, gender, and duration of ractopamine on belly and bacon quality traits. Meat Sci. 200

萊克多巴胺(97825-25-7,Ractopaminehydrochloride,El 737,LY-031537)參考文獻：

1、Phosphorene nanocomposite with high environmental stability and antifouling capability for simultaneous sensing of clenbuterol and ractopamine
Yu Ge 1 2, Mingren Qu 1, Lanjiao Xu 3, Xiaoqiang Wang 2, Junping Xin 1, Xiaoning Liao 2, Meifa Li 1, Mingfang Li 2, Yangping Wen

Abstract A series of phosphorene (BP) nanocomposites was prepared to realize simultaneous electrochemical determination of clenbuterol (CLB) and ractopamine (RAC). CLB and RAC are the most commonly used β-agonists in animal-derived food. The BP nanohybrid was obtained by co-decoration with both mono(6-mercapto-6-deoxy)-β-cyclodextrin and poly(3,4-ethylenedioxythiophene) nanoparticles. It displays high stability, antifouling capability, a large electrochemical active surface and good electrochemical response. The electrochemical assisted antifouling strategy was selected by further eliminating the fouling of the electrode surface using continuous cyclic voltammetry. The electrode was employed for electrochemical sensing of CLB and RAC at typical peak voltages of 0.8 and 1.0 V (vs. SCE). Responses are linear in the 0.3-90 μM concentration range for CLB, and from 0.3 to 9.4 μM for RAC under optimal conditions. The limit of detection are 0.14 and 0.12 μM, respectively. The sensor was employed for simultaneous determination of CLB and RAC in (spiked) beef, feed and bovine serum samples with acceptable recoveries. Graphical abstractAn electrochemically assisted anti-fouling method for simultaneous voltammetric nanosensing of clenbuterol (CLB) and ractopamine (RAC) in edible cattle product samples using high-stable and anti-foul phosphorene (BP) co-decorated with mono(6-mercapto-6-deoxy)-β-cyclodextrin (S-β-CD) and poly(3,4-ethylenedioxythiophene) (PEDOTNPs).

2、Detection of Six β-Agonists by Three Multiresidue Immunosensors Based on an Anti-bovine Serum Albumin-Ractopamine-Clenbuterol-Salbutamol Antibody
Chenxi Gu 1, Pengfei Ren 1, Fan Zhang 1, Guozheng Zhao 2, Jian Shen 1, Bo Zhao

Abstract According to an indirect competitive immunoassay, six β-agonists (clenbuterol (CL), salbutamol (SAL), ractopamine (RAC), terbutaline (TER), mabuterol (MAB), and tulobuterol (TUL)) were detected by three novel multiresidue immunosensors on the basis of the successful preparation of bovine serum albumin (BSA)-RAC-CL-SAL multideterminant antigen and anti-BSA-RAC-CL-SAL antibody. A new strategy was reported to detect six β-agonists by combining nanotechnology, electrochemical detection, and specific immune technology. At the same concentration, the amperometric response for detection of six β-agonists was in a sequence of GCE/GNP/SAL > GCE/GNP/RAC > GCE/GNP/CL. Detection limits of six β-agonists show that the multiresidue detection performance of the GCE/GNP/RAC immunosensor is better than those of GCE/GNP/SAL and GCE/GNP/CL immunosensors. Three immunosensors manifest superior properties with a wide linear range, low detection limit, excellent reproducibility, and stability. The proposed GCE/GNP/RAC immunosensor displays high accuracy and can be effectively used for real sample detection.

3、Synthesis of 3D magnetic porous carbon derived from a metal-organic framework for the extraction of clenbuterol and ractopamine from mutton samples
Xinyang Zhang 1, Jianan Wen 1, Lili Lian 1, Xianhong Ma 1, Xiyue Wang 1, Dawei Lou

Abstract 3D magnetic porous carbon (MPCK) was prepared using the metal-organic framework (MOF) MIL-100(Fe) as the carbon precursor by carbonisation and KOH activation strategies. Carbonisation and activation ensured that MPCK possessed excellent structural and thermal stability, strong magnetic responsiveness and high surface area. MPCK was used as an adsorbent for the magnetic solid-phase extraction of clenbuterol and ractopamine from mutton samples. The concentration levels of analytes were determined by ultra-high performance liquid chromatography-mass spectrometry. Under optimised extraction conditions, the peak area responded linearly to analytes over the concentration range from 0.05 μg L-1 to 40 μg L-1 (r ≥ 0.9972). The detection limits of clenbuterol and ractopamine were found to be 0.130 μg kg-1 and 0.150 μg kg-1, respectively. The satisfactory recoveries in mutton samples ranging from 95.64% to 114.65% indicated that 3D porous carbon is a promising adsorption material for the extraction of clenbuterol and ractopamine from complex biological matrixes.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開